67 related articles for article (PubMed ID: 21246790)
21. [Inactivation of BRCA1, BRCA2 and p53 genes in sporadic ovarian cancer].
Zikán M; Pohlreich P; Freitag P; Janousek M; Pavlista D; Fischerová D; Jancárková N; Sláma J; Pinkavová I; Cibula D
Ceska Gynekol; 2008 Oct; 73(5):298-302. PubMed ID: 19110958
[TBL] [Abstract][Full Text] [Related]
22. Borderline epithelial tumours of the ovary--a retrospective analysis of 31 cases.
Kane SV; Bharadwaj R; Tongaonkar HB
Indian J Cancer; 1999 Mar; 36(1):18-31. PubMed ID: 10810551
[TBL] [Abstract][Full Text] [Related]
23. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
24. Molecular pathology of epithelial ovarian cancer.
Christie M; Oehler MK
J Br Menopause Soc; 2006 Jun; 12(2):57-63. PubMed ID: 16776856
[TBL] [Abstract][Full Text] [Related]
25. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
26. Epithelial ovarian tumors of borderline malignancy.
Chao TM; Yen MS; Chao KC; Ng HT
Zhonghua Yi Xue Za Zhi (Taipei); 1996 Aug; 58(2):97-102. PubMed ID: 8915111
[TBL] [Abstract][Full Text] [Related]
27. An apoptotic molecular network identified by microarray: on the TRAIL to new insights in epithelial ovarian cancer.
Ouellet V; Le Page C; Madore J; Guyot MC; Barrès V; Lussier C; Tonin PN; Provencher DM; Mes-Masson AM
Cancer; 2007 Jul; 110(2):297-308. PubMed ID: 17569106
[TBL] [Abstract][Full Text] [Related]
28. [Preliminary study of neuroendocrine differentiation and its mechanism in ovarian epithelial tumors].
Jiang LY; Wang ZN; Luo X; Xu JP; Xie XM
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jul; 27(7):1081-3. PubMed ID: 17666356
[TBL] [Abstract][Full Text] [Related]
29. High-resolution genomic profiling of carboplatin resistance in early-stage epithelial ovarian carcinoma.
Osterberg L; Levan K; Partheen K; Staaf J; Sundfeldt K; Horvath G
Cytogenet Genome Res; 2009; 125(1):8-18. PubMed ID: 19617691
[TBL] [Abstract][Full Text] [Related]
30. Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms.
Giordano G; Azzoni C; D'Adda T; Rocco A; Gnetti L; Froio E; Merisio C; Melpignano M
Pathol Res Pract; 2008; 204(3):163-74. PubMed ID: 18180113
[TBL] [Abstract][Full Text] [Related]
31. [Recommendation for genetic testing in patients suffering from gynecological malignancy].
Zikán M
Ceska Gynekol; 2015 Mar; 80(2):97-103. PubMed ID: 25944599
[TBL] [Abstract][Full Text] [Related]
32. [Transabdominal ultrasound examination in gynecology].
Zikán M; Fischerová D; Sláma J; Pinkavová I; Cibula D
Ceska Gynekol; 2011 Sep; 76(4):252-7. PubMed ID: 22026064
[TBL] [Abstract][Full Text] [Related]
33. [BORDERLINE OVARIAN TUMORS: CURRENT ISSUES AND REHABILITATION PROBLEMS].
Solopova A; Vlasina A; Makatsariya A; Moskvichyova V; Kapanadze D
Georgian Med News; 2018 Nov; (284):7-13. PubMed ID: 30618380
[TBL] [Abstract][Full Text] [Related]
34. [Proteomics and its importance for gynecological oncology].
Lacheta J; Cibula D; Freitag P; Zivný J
Ceska Gynekol; 2004 Sep; 69(5):384-7. PubMed ID: 15587895
[TBL] [Abstract][Full Text] [Related]
35. The management of borderline epithelial tumors of the ovary.
Burger CW; Prinssen HM; Baak JP; Wagenaar N; Kenemans P
Int J Gynecol Cancer; 2000 May; 10(3):181-197. PubMed ID: 11240673
[TBL] [Abstract][Full Text] [Related]
36. Ovarian cancer: pathology, biology, and disease models.
Rosen DG; Yang G; Liu G; Mercado-Uribe I; Chang B; Xiao XS; Zheng J; Xue FX; Liu J
Front Biosci (Landmark Ed); 2009 Jan; 14(6):2089-102. PubMed ID: 19273186
[TBL] [Abstract][Full Text] [Related]
37. [The incidence of ovarian cancer in the First Gynecological Hospital of Charles University].
DVORAK O
Cesk Gynekol; 1959 Jul; 24():463-7. PubMed ID: 13818954
[No Abstract] [Full Text] [Related]
38. [Molecular characterization of epithelial ovarian borderline tumors with respect to clinical management and prognosis].
Zikán M; Pinkavová I; Sláma J; Freitag P; Janousek M; Fischerová D; Pavlista D; Cibula D
Ceska Gynekol; 2009 Dec; 74(6):427-30. PubMed ID: 21246790
[TBL] [Abstract][Full Text] [Related]
39. Triple negative epithelial ovarian cancer: "A new entity".
Jain P; Jain A; Dubashi B
Indian J Cancer; 2015; 52(2):190. PubMed ID: 26853398
[No Abstract] [Full Text] [Related]
40. [Histopathologic prognostic factors, serum markers and selected molecular biologic factors in ovarian carcinoma].
Spacek J; Jílek P; Petera J; Tesarík Z
Ceska Gynekol; 2002 Nov; 67(6):343-9. PubMed ID: 12661373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
